Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with previously-treated multiple myeloma live for a median 33 months without the blood cancer getting worse in a Phase II trial. The drug was given with Celgene's (CELG) Revlimid and the steroid dexamethasone. Elotuzumab is also being tested in two Phase III trials for multiple myeloma. (PR)